A powerful signal is flashing across India’s innovation landscape: deep-tech is no longer a niche—it’s the new mainstream. With funding in the sector surging 53% to $690 million in H1 FY26, a new wave of startups building in EV infrastructure, semiconductors, quantum communications, and space-tech is actively lining up significant capital rounds. This isn’t the tentative, exploratory funding of a few years ago; it is growth-stage conviction from top-tier investors like 360 One, BIG Capital, Accel, and Avaana Capital, backing ventures with proven business models, defensible IP, and clear paths to scaling.

In a powerful endorsement of India’s growing capabilities in healthcare innovation, global pharmaceutical leader Pfizer has selected 14 Indian health-tech startups for its INDovation 2026 cohort, awarding each ₹60 lakh in grant funding along with deep, structured incubation support. With a total commitment exceeding ₹8.4 crore in non-dilutive capital, this initiative is far more than a corporate social responsibility gesture; it is a strategic play to tap into India’s vibrant ecosystem of frugal, scalable health-tech solutions and co-create the future of accessible medicine.